Product Description
Aceclidine has been marketed in Europe but has not been used clinically in the United States. It is used in the treatment of open-angle glaucoma and is a parasympathomimetic agent.
Mechanisms of Action: mAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Germany | Greece | Italy | Peru | Portugal
Approved Indications: None
Known Adverse Events: None
Company: Ji Xing Pharmaceuticals (Shanghai)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Presbyopia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05431543 | P2 |
Completed |
Presbyopia |
2022-12-14 |
|
| NCT05294328 | P2 |
Completed |
Presbyopia |
2022-08-22 |